{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:49:06Z","timestamp":1773467346278,"version":"3.50.1"},"reference-count":47,"publisher":"Medical Association of Nippon Medical School","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2026,2,20]]},"DOI":"10.1272\/jnms.jnms.2026_93-111","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:09:35Z","timestamp":1773180575000},"page":"49-59","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of Pathologically Negative Sentinel Lymph Nodes and Recurrence-Free Survival in Women with Invasive Breast Cancer Treated with Neoadjuvant Chemotherapy"],"prefix":"10.1272","volume":"93","author":[{"given":"Phanchaporn","family":"Wongmaneerung","sequence":"first","affiliation":[{"name":"Division of Head, Neck and Breast, Department of Surgery, Faculty of Medicine, Chiang Mai University"},{"name":"Clinical Surgical Research Center, Chiang Mai University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Kurita","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meishi","family":"Hankyo","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Tama Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sakatani","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Kumita","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nippon Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71 (3):209-49. Epub 2021 Feb 4. doi: 10.3322\/caac.21660. PubMed PMID: 33538338","DOI":"10.3322\/caac.21660"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Abass MO, Gismalla MDA, Alsheikh AA, Elhassan MMA. Axillary lymph node dissection for breast cancer: Efficacy and complication in developing Countries. J Glob Oncol. 2018;4:1-8. doi: 10.1200\/JGO.18.00080. PubMed PMID: 30281378; PubMed Central PMCID: PMC6223503","DOI":"10.1200\/JGO.18.00080"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kuehn T, Klauss W, Darsow M, et al. Long-term morbidity following axillary dissection in breast cancer patients--clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat. 2000;64 (3):275-86. doi: 10.1023\/a:1026564723698. PubMed PMID: 11200778","DOI":"10.1023\/A:1026564723698"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Janni W, Kuhn T, Schwentner L, Kreienberg R, Fehm T, Wockel A. Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits. Dtsch Arztebl Int. 2014;111 (14):244-9. doi: 10.3238\/arztebl.2014.0244. PubMed PMID: 24766712; PubMed Central PMCID: PMC4003445","DOI":"10.3238\/arztebl.2014.0244"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Guenther JM, Hansen NM, DiFronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003;138 (1):52-6. doi: 10.1001\/archsurg.138.1.52. PubMed PMID: 12511150","DOI":"10.1001\/archsurg.138.1.52"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Magnoni F, Galimberti V, Corso G, Intra M, Sacchini V, Veronesi P. Axillary surgery in breast cancer: an updated historical perspective. Semin Oncol. 2020;47 (6):341-52. Epub 2020 Oct 23. doi: 10.1053\/j.seminoncol.2020.09.001. PubMed Central PMCID: 33131896","DOI":"10.1053\/j.seminoncol.2020.09.001"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129 (3):675-89. Epub 2011 Jul 9. doi: 10.1007\/s10549-011-1665-1. PubMed PMID: 21743996","DOI":"10.1007\/s10549-011-1665-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305 (6):569-75. doi: 10.1001\/jama.2011.90. PubMed PMID: 21304082; PubMed Central PMCID: PMC5389857","DOI":"10.1001\/jama.2011.90"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Gipponi M, Bassetti C, Canavese G, et al. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J Surg Oncol. 2004;85 (3):102-11. doi: 10.1002\/jso.20022. PubMed PMID: 14991881","DOI":"10.1002\/jso.20022"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Chen Y, Shi XE, Tian JH, Yang XJ, Wang YF, Yang KH. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: a meta-analysis. Medicine (Baltimore). 2018;97 (20):e10634. doi: 10.1097\/MD.0000000000010634. PubMed PMID: 29768327; PubMed Central PMCID: PMC5976345","DOI":"10.1097\/MD.0000000000010634"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26 (12):2838-48. Epub 2020 Feb 11. doi: 10.1158\/1078-0432.CCR-19-3492. PubMed PMID: 32046998; PubMed Central PMCID: PMC7299787","DOI":"10.1158\/1078-0432.CCR-19-3492"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Kim MM, Allen P, Gonzalez-Angulo AM, et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013;24 (8):1999-2004. Epub 2013 Apr 5. doi: 10.1093\/annonc\/mdt131. PubMed PMID: 23562929; PubMed Central PMCID: PMC3718505","DOI":"10.1093\/annonc\/mdt131"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. An SJ, Duchesneau ED, Strassle PD, et al. Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2\/N0 HER2+ breast cancer. NPJ Breast Cancer. 2022;8 (1):65. doi: 10.1038\/s41523-022-00433-x. PubMed PMID: 35552411; PubMed Central PMCID: PMC9098414","DOI":"10.1038\/s41523-022-00433-x"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Bonnefoi H, Litiere S, Piccart M, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994\/BIG 1-00 phase III trial. Ann Oncol. 2014;25 (6):1128-36. Epub 2014 Mar 11. doi: 10.1093\/annonc\/mdu118. PubMed PMID: 24618153; PubMed Central PMCID: PMC4037859","DOI":"10.1093\/annonc\/mdu118"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Broglio KR, Quintana M, Foster M, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2016;2 (6):751-60. doi: 10.1001\/jamaoncol.2015.6113. PubMed PMID: 26914222","DOI":"10.1001\/jamaoncol.2015.6113"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Gerber B, Schneeweiss A, Mobus V, et al. Pathological response in the breast and axillary lymph nodes after neoadjuvant systemic treatment in patients with initially node-positive breast cancer correlates with disease free survival: an exploratory analysis of the GeparOcto Trial. Cancers (Basel). 2022;14 (3):521. doi: 10.3390\/cancers14030521. PubMed PMID: 35158789; PubMed Central PMCID: PMC8833390","DOI":"10.3390\/cancers14030521"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45 (18):3124-30. Epub 2009 Aug 26. doi: 10.1016\/j.ejca.2009.08.001. PubMed PMID: 19716287","DOI":"10.1016\/j.ejca.2009.08.001"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16 (5):551-63. doi: 10.1016\/j.acra.2009.01.026. PubMed PMID: 19345896","DOI":"10.1016\/j.acra.2009.01.026"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. de Wild SR, Simons JM, Vrancken Peeters MTFD, Smidt ML, Koppert LB. De-escalating axillary surgery in node-positive breast cancer treated with neoadjuvant systemic therapy. Breast Care (Basel). 2021;16 (6):584-9. Epub 2021 Aug 17. doi: 10.1159\/000518376. PubMed PMID: 35087361; PubMed Central PMCID: PMC8739383","DOI":"10.1159\/000518376"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. van der Noordaa MEM, van Duijnhoven FH, Cuijpers FNE, et al. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer. Br J Surg. 2021;108 (6):667-74. doi: 10.1002\/bjs.12026. PubMed PMID: 34157085","DOI":"10.1002\/bjs.12026"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Hersh EH, King TA. De-escalating axillary surgery in early-stage breast cancer. Breast. 2022;62 (Suppl 1):S43-9. Epub 2021 Dec 15. doi: 10.1016\/j.breast.2021.11.018. PubMed PMID: 34949533; PubMed Central PMCID: PMC9097808","DOI":"10.1016\/j.breast.2021.11.018"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017;152 (7):665-70. doi: 10.1001\/jamasurg.2017.1632. PubMed PMID: 28423171; PubMed Central PMCID: PMC5547923","DOI":"10.1001\/jamasurg.2017.1632"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Pfob A, Heil J. Breast and axillary surgery after neoadjuvant systemic treatment - a review of clinical routine recommendations and the latest clinical research. Breast. 2022;62 (Suppl 1):S7-11. Epub 2022 Jan 22. doi: 10.1016\/j.breast.2022.01.008. PubMed PMID: 35135710; PubMed Central PMCID: PMC9097799","DOI":"10.1016\/j.breast.2022.01.008"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Simons JM, van Nijnatten TJA, van der Pol CC, Luiten EJT, Koppert LB, Smidt ML. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019;269 (3):432-42. doi: 10.1097\/SLA.0000000000003075. PubMed PMID: 30312200; PubMed Central PMCID: PMC6369968","DOI":"10.1097\/SLA.0000000000003075"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Tee SR, Devane LA, Evoy D, et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg. 2018;105 (12):1541-52. doi: 10.1002\/bjs.10986. PubMed PMID: 30311642","DOI":"10.1002\/bjs.10986"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Stankowski-Drengler TJ, Neuman HB. Management of the axilla after neoadjuvant systemic therapy. Curr Treat Options Oncol. 2020;21 (7):54. doi: 10.1007\/s11864-020-00755-7. PubMed PMID: 32462230; PubMed Central PMCID: PMC7474973","DOI":"10.1007\/s11864-020-00755-7"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48 (18):3342-54. Epub 2012 Jul 3. doi: 10.1016\/j.ejca.2012.05.023. PubMed PMID: 22766518","DOI":"10.1016\/j.ejca.2012.05.023"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Bi Z, Liu J, Chen P, et al. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla. Breast Cancer. 2019;26 (3):373-7. Epub 2019 Jan 21. doi: 10.1007\/s12282-018-00934-3. PubMed PMID: 30666563","DOI":"10.1007\/s12282-018-00934-3"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Pilewskie M, Zabor EC, Mamtani A, Barrio AV, Stempel M, Morrow M. The optimal treatment plan to avoid axillary lymph node dissection in early-stage breast cancer patients differs by surgical strategy and tumor subtype. Ann Surg Oncol. 2017;24 (12):3527-33. Epub 2017 Jul 31. doi: 10.1245\/s10434-017-6016-y. PubMed PMID: 28762114; PubMed Central PMCID: PMC5697709","DOI":"10.1245\/s10434-017-6016-y"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Otsuka T, Matsuyama K. Nippon Medical School's ethical review processes for studies involving human subjects. J Nippon Med Sch. 2024;91 (2):136-9. doi: 10.1272\/jnms.JNMS.2024_91-216. PubMed PMID: 38777779","DOI":"10.1272\/jnms.JNMS.2024_91-216"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310 (14):1455-61. doi: 10.1001\/jama.2013.278932. PubMed PMID: 24101169; PubMed Central PMCID: PMC4075763","DOI":"10.1001\/jama.2013.278932"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Boughey JC, Suman VJ, Mittendorf EA, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015;261 (3):547-52. doi: 10.1097\/SLA.0000000000000551. PubMed PMID: 25664534; PubMed Central PMCID: PMC4324533","DOI":"10.1097\/SLA.0000000000000551"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Geng C, Chen X, Pan X, Li J. The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis. PLoS One. 2016;11 (9):e0162605. doi: 10.1371\/journal.pone.0162605. PubMed PMID: 27606623; PubMed Central PMCID: PMC5015960","DOI":"10.1371\/journal.pone.0162605"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Uren RF, Howman-Giles R, Chung DK, et al. SPECT\/CT scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla. Breast. 2012;21 (4):480-6. Epub 2011 Dec 5. doi: 10.1016\/j.breast.2011.11.007. PubMed PMID: 22153573","DOI":"10.1016\/j.breast.2011.11.007"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Vermeeren L, van der Ploeg IM, Olmos RA, et al. SPECT\/CT for preoperative sentinel node localization. J Surg Oncol. 2010;101 (2):184-90. doi: 10.1002\/jso.21439. PubMed PMID: 19924723","DOI":"10.1002\/jso.21439"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Laot L, Laas E, Girard N, et al. The prognostic value of lymph node involvement after neoadjuvant chemotherapy is different among breast cancer subtypes. Cancers (Basel). 2021;13 (2):171. doi: 10.3390\/cancers13020171. PubMed PMID: 33418983; PubMed Central PMCID: PMC7825348","DOI":"10.3390\/cancers13020171"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Zheng W, Zhou P, Liu Y, Liang Y, Wang Y. Prediction of axillary response after neoadjuvant chemotherapy in clinical node positive breast cancer. Transl Cancer Res. 2021;10 (6):2822-30. doi: 10.21037\/tcr-20-3454. PubMed PMID: 35116592; PubMed Central PMCID: PMC8797863","DOI":"10.21037\/tcr-20-3454"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260 (4):608-14; discussion 614-6. doi: 10.1097\/SLA.0000000000000924. PubMed PMID: 25203877; PubMed Central PMCID: PMC4159769","DOI":"10.1097\/SLA.0000000000000924"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268 (4):591-601. doi: 10.1097\/SLA.0000000000002953. PubMed PMID: 30048319; PubMed Central PMCID: PMC6496955","DOI":"10.1097\/SLA.0000000000002953"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Boland MR, McVeigh TP, O'Flaherty N, et al. Impact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy. BJS Open. 2017;1 (2):39-45. doi: 10.1002\/bjs5.6. PubMed PMID: 29951604; PubMed Central PMCID: PMC5989970","DOI":"10.1002\/bjs5.6"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Samiei S, Simons JM, Engelen SME, et al. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg. 2021;156 (6):e210891. Epub 2021 Jun 9. doi: 10.1001\/jamasurg.2021.0891. PubMed PMID: 33881478; PubMed Central PMCID: PMC8060891","DOI":"10.1001\/jamasurg.2021.0891"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Vila J, Mittendorf EA, Farante G, et al. Nomograms for predicting axillary response to Neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol. 2016;23 (11):3501-9. Epub 2016 May 23. doi: 10.1245\/s10434-016-5277-1. PubMed PMID: 27216742","DOI":"10.1245\/s10434-016-5277-1"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43. Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis. Ann Surg Oncol. 2019;26 (11):3517-25. Epub 2019 Jul 24. doi: 10.1245\/s10434-019-07583-6. PubMed PMID: 31342389","DOI":"10.1245\/s10434-019-07583-6"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380 (7):617-28. Epub 2018 Dec 5. doi: 10.1056\/NEJMoa1814017. PubMed PMID: 30516102","DOI":"10.1056\/NEJMoa1814017"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376 (22):2147-59. doi: 10.1056\/NEJMoa1612645. PubMed PMID: 28564564","DOI":"10.1056\/NEJMoa1612645"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30 (15):1796-804. Epub 2012 Apr 16. doi: 10.1200\/JCO.2011.38.8595. PubMed PMID: 22508812","DOI":"10.1200\/JCO.2011.38.8595"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47. LeVasseur N, Sun J, Gondara L, et al. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis. J Cancer Res Clin Oncol. 2020;146 (2):529-36. Epub 2019 Nov 18. doi: 10.1007\/s00432-019-03083-y. PubMed PMID: 31741041; PubMed Central PMCID: PMC11804444","DOI":"10.1007\/s00432-019-03083-y"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/93\/1\/93_JNMS.2026_93-111\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:49:44Z","timestamp":1773463784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/93\/1\/93_JNMS.2026_93-111\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2026_93-111","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"JNMS.2026_93-111"}}